Titolo:  Insights into Ebola Virus VP35 and VP24 Interferon inhibitory functions and their initial exploitation as drug targets
Data di pubblicazione:  2019
Data di prima pubblicazione on-line:  2019
Autori: 
Autori:  Fanunza, Elisa; Frau, Aldo; Corona, Angela; Tramontano, Enzo
Numero degli autori:  4
Lingua:  Inglese
Presenza coautori internazionali:  no
Rivista:  INFECTIOUS DISORDERS - DRUG TARGETS
Volume:  19
Fascicolo:  4
Pagina iniziale:  362
Pagina finale:  374
Numero di pagine:  21
Digital Object Identifier (DOI):  http://dx.doi.org/10.2174/1871526519666181123145540
Codice identificativo Pubmed:  30468131
Codice identificativo Scopus:  2-s2.0-85075467328
URL:  http://www.eurekaselect.com/167703/article
Abstract:  Upon viral infection, the interferon (IFN) system triggers potent antiviral mechanisms limiting viral growth and spread. Hence, to sustain their infection, viruses evolved efficient counteracting strategies to evade IFN control. Ebola virus (EBOV), member of the family Filoviridae, is one of the most virulent and deadly pathogen ever faced by humans. Etiological agent of the Ebola virus disease (EVD), EBOV can be undoubtedly considered the perfect example of a powerful inhibitor of the host organism immune response activation. Particularly, the efficacious suppression of the IFN cascade contributes to disease progression and severity. Among the EBOV-encoded proteins, the viral proteins 35 (VP35) and 24 (VP24) are responsible for the EBOV extreme virulence, representing the core of such inhibitory function through which EBOV determines its very effective shield to the cellular immune defenses. VP35 inhibits the activation of the cascade leading to IFN production, while VP24 inhibits the activation of the IFN-stimulated genes. A number of studies demonstrated that both VP35 and VP24 are validated target for drug development. Insights of the structural characteristics of VP35 and VP24 domains revealed crucial pockets exploitable for drug development. Considered the lack of therapy for EVD, restoring the immune activation is a promising approach for drug development. In the present review we summarize the importance of VP35 and VP24 proteins in counteracting the host IFN cellular response and discuss their potential as druggable viral targets as a promising approach toward attenuation of EBOV virulence.
Parole chiave:  Ebola virus; FDA approved drugEbola virus; FDA approved drugs; IFN production; IFN signaling; Interferon; VP24; VP35; small molecules
Tipologia: 1.1 Articolo in rivista

File in questo prodotto:
File Descrizione Tipologia Licenza  
2018 Fanunza et al submitted.pdf  Bozza sottomesssa, versione pre-referaggio versione pre-print Open Access Visualizza/Apri

Questionario e social

Condividi su: